Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Tel Aviv Sourasky Medical Center Emergency Department study group

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)137-139
Number of pages3
JournalEuropean Journal of Internal Medicine
StatePublished - Jun 2022


  • BNT162b2 vaccine
  • Casirivimab/Imdevimab therapy
  • High-risk patients
  • SARS-CoV-2 delta variant
  • Severe outcome

Cite this